Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients

[1]  Ming Yan,et al.  RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. , 2012, Blood.

[2]  E. Bouhassira,et al.  Zinc-finger nuclease-mediated correction of α-thalassemia in iPS cells. , 2012, Blood.

[3]  R. Hardison,et al.  Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells , 2012, Proceedings of the National Academy of Sciences.

[4]  Shinsuke Yuasa,et al.  Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus , 2012, Nature Protocols.

[5]  M. Loh,et al.  Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. , 2011, Blood.

[6]  G. Daley,et al.  Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells , 2011, Proceedings of the National Academy of Sciences.

[7]  R. Khokha,et al.  TIMP-3 recruits quiescent hematopoietic stem cells into active cell cycle and expands multipotent progenitor pool. , 2010, Blood.

[8]  H. Aburatani,et al.  Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. , 2010, Blood.

[9]  A. Jones,et al.  Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms , 2010, Haematologica.

[10]  Shinsuke Yuasa,et al.  Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. , 2010, Cell stem cell.

[11]  R. Jaenisch,et al.  Generation of iPSCs from cultured human malignant cells. , 2010, Blood.

[12]  S. K. Zaidi,et al.  Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation. , 2010, Human molecular genetics.

[13]  C. Dang,et al.  Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. , 2009, Blood.

[14]  H. Harada,et al.  Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations , 2009, Journal of cellular physiology.

[15]  D. Liang,et al.  RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation , 2009, Leukemia.

[16]  J. Thomson,et al.  Hematopoietic and Endothelial Differentiation of Human Induced Pluripotent Stem Cells , 2009, Stem cells.

[17]  Georges Lacaud,et al.  The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage , 2009, Nature.

[18]  Elaine Dzierzak,et al.  Runx1 is required for the endothelial to hematopoietic cell transition but not thereafter , 2009, Nature.

[19]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[20]  H. Nakauchi,et al.  Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis , 2008, Proceedings of the National Academy of Sciences.

[21]  M. Hoshi,et al.  High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site. , 2008, Journal of radiation research.

[22]  H. Nakauchi,et al.  Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. , 2008, Blood.

[23]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[24]  D. Littman,et al.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. , 2007, Blood.

[25]  D. Littman,et al.  Runx1 Protects Hematopoietic Stem/Progenitor Cells from Oncogenic Insult , 2007, Stem cells.

[26]  T. Nakahata,et al.  Novel Method for Efficient Production of Multipotential Hematopoietic Progenitors from Human Embryonic Stem Cells , 2007, International journal of hematology.

[27]  Patrick R. Cushing,et al.  Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant‐negative, or hypomorphic alleles , 2007, The EMBO journal.

[28]  J. Thomson,et al.  Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. , 2006, Blood.

[29]  Hideaki Nakajima,et al.  Comprehensive analysis of myeloid lineage conversion using mice expressing an inducible form of C/EBPα , 2006, The EMBO journal.

[30]  M. Andersen,et al.  Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. , 2004, Blood.

[31]  Motomi Osato.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia , 2004, Oncogene.

[32]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[33]  S. Ogawa,et al.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis , 2004, Nature Medicine.

[34]  T. Inaba,et al.  Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. , 2003, Blood.

[35]  Elaine Dzierzak,et al.  Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. , 2002, Immunity.

[36]  Yoshiaki Ito,et al.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.

[37]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[38]  M. Kurokawa,et al.  Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. , 2000, Blood.

[39]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[40]  T. Gu,et al.  Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. , 1999, Development.

[41]  A. Miyajima,et al.  Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cell lines. , 1998, Blood.

[42]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[44]  平本 貴史.  Wnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia patient-derived pluripotent stem cells , 2013 .

[45]  B. Thiers.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .